Maribavir use in practice for cytomegalovirus infection in french transplantation centers

Transplantation Proceedings

Volumn 45, Issue 4, 2013, Pages 1603-1607

  Alain, S ^a   Revest, M ^b   Veyer, D ^b   Essig, M ^c   Rerolles, J P ^c   Rawlinson, W ^a,d   Mengelle, C ^e   Huynh, A ^e   Kamar, N ^e   Garrigue, I ^f   Kaminski, H ^f   Segard, C ^g   Presne, C ^g   Mazeron, M C ^h   Avettant Fenoel V ⁱ   Lecuit, M ⁱ   Lortholary, O ⁱ   Coaquette, A ^j   Hantz, S ^a   Leruez Ville, M ⁱ   Ploy, M C ^a   more..

^a UNIVERSITY OF LIMOGES   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h Laboratoire de Virologie   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; CORTICOSTEROID; FOSCARNET; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; BONE MARROW; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; FIBROBLAST; GENE SEQUENCE; GENOTYPE; GRAFT RECIPIENT; HUMAN; IC 50; MALE; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FRANCE; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ORGAN TRANSPLANTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RIBONUCLEOSIDES;

EID: 84878608183     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.01.082     Document Type: Conference Paper

References (15)

1. S. Hantz, F. Garnier-Geoffroy, M.C. Mazeron Drug-resistant cytomegalovirus in transplant recipients: a French cohort study J Antimicrob Chemother 65 2010 2628 2640
2. G. Boivin, N. Goyette, C. Gilbert, E. Covington Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis J Med Virol 77 2005 425 429
3. G. Boivin, N. Goyette, H. Rollag Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir Antivir Ther 14 2009 697 704
4. A.J. Eid, S.K. Arthurs, P.J. Deziel, M.P. Wilhelm, R.R. Razonable Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes Clin Transplant 22 2008 162 170
5. H. Lu, S. Thomas Maribavir (ViroPharma) Curr Opin Investig Drugs 5 2004 898 906
6. S. Chou, M. Hakki, S. Villano Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo Antiviral Res 95 2012 88 92
7. F.M. Marty, M. Boeckh Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol 1 2011 555 562
8. F.M. Marty, P. Ljungman, G.A. Papanicolaou Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial Lancet Infect Dis 11 2011 284 292
9. R.K. Avery, F.M. Marty, L. Strasfeld Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients Transpl Infect Dis 12 2010 489 496
10. S. Alain, S. Hantz, C. Scieux Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection J Med Virol 73 2004 566 573
11. A. Ducancelle, S. Belloc, S. Alain Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy J Clin Virol 29 2004 241 247
12. S. Chou Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir Rev Med Virol 18 2008 233 246
13. N.S. Lurain, S. Chou Antiviral drug resistance of human cytomegalovirus Clin Microbiol Rev 23 2010 689 712
14. D.R. Snydman Why did maribavir fail in stem-cell transplants? Lancet Infect Dis 11 2011 255 257
15. M. Hakki, C. Drummond, B. Houser, G. Marousek, S. Chou Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection Antiviral Res 92 2011 313 318